



IFW

Please type a plus sign (+) inside this box → [+]

PTO/SB/21 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM <i>(to be used for all correspondence after initial filing)</i>		Application Number	10/686,619
		Filing Date	October 17, 2003
		First Named Inventor	Margot Mary O'TOOLE, et al.
		Group Art Unit	1614
		Examiner Name	N/A
Total Number of Pages in This Submission	4	Attorney Docket Number	031896-004000 (AM 100990)

ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Assignment Papers (for an Application) <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Declaration and Power of Attorney <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input type="checkbox"/> Application Data Sheet <input checked="" type="checkbox"/> Other Enclosure(s): Copies of references
Remarks		<input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees required or credit any overpayments to Deposit Account No. 19-2380 (740819-383) for the above identified docket number.

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	<u>Raymond Van Dyke, Reg. No. 34,746</u> Nixon Peabody LLP 409 9 th Street, N.W. Suite 900 Washington, D.C. 20004-2128
Signature	
Date	February 23, 2005

CERTIFICATE OF MAILING	
CERTIFICATE OF MAILING OR TRANSMISSION [37 CFR 1.8(a)]	
I hereby certify that this correspondence is being:	
<input type="checkbox"/> deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450	
<input type="checkbox"/> transmitted by facsimile on the date shown below to the United States Patent and Trademark Office at _____	
Date	Signature



Application No. 10/686,619
Docket No. 031896-004000 (AM100990)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

Margot Mary O'TOOLE et al.

Examiner: Theresa Frederick

Serial No. 10/686,619

Group Art Unit: 1614

Filed: October 17, 2003

For: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING
AUTOMIMUNE DISEASE

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. §1.56, Applicants hereby submit the following information in conformance with 37 C.F.R. §§ 1.97 and 1.98. Pursuant to 37 C.F.R. § 1.98, a copy of each of the documents cited is enclosed.


The documents are being submitted within three (3) months of the filing of this application or entry into the national stage of this application, or before the first Office Action on the merits, whichever is later, therefore no fee or certification is required under 37 C.F.R. § 1.97(b).

It is requested that the accompanying PTO-1449 be considered and made of record in the above-identified application. To assist the Examiner, the documents are listed on the attached form PTO-1449. It is respectfully requested that an Examiner initial a copy of this form be returned to the undersigned.

The Commissioner is hereby authorized to charge any fees connected with this filing which may be required now, or credit any overpayment to Deposit Account No. 19-2380.

Respectfully submitted,

By:




Raymond Van Dyke
Registration No. 34,746

NIXON PEABODY LLP
Suite 900
401 9th Street, N.W.
Washington, DC 20004-2128

Telephone: (202) 585-8000

Date: February 23, 2005




Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	10/686,619
				Filing Date	October 17, 2003
				First Named Inventor	Margot Mary O'TOOLE et al.
				Art Unit	1614
				Examiner Name	Theresa Frederick
Sheet	1	of	2	Attorney Docket Number	031896-004000 (AM100990)

U.S. PATENT DOCUMENTS					
Examiner Initials [*]	Cite No. ¹	U.S. Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code ³	Number ⁴ Kind Code ⁵ (if known)			
		EP	1 215 500 A	06-19-2002	Muramatsu	

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		MISHIMA, et al., "Increased expression of midkine during the progression of human astrocytomas", <i>Neuroscience Letters</i> , Vol., 233, No. 1, pages 29-32, (1997)	
		TSUTSUI, et al., "A new family of heparin-binding growth/differentiation factors: Increased midkine expression in Wilms' tumor and other human carcinomas", <i>Cancer Research</i> , Vol. 53, No. 6, pages 1281-1285, (1993)	
		KUROSAWA, et al., "Midkine binds specifically to sulfatide. The role of sulfatide in cell attachment to midkine-coated surfaces", <i>European Journal of Biochemistry</i> , Vol. 267, No. 2, January 2000	
		ZOU, et al., "A heparin-binding growth factor, midkine, binds to a chondroitin sulfate proteoglycan, PG-M/versican", <i>European Journal of Biochemistry</i> , Vol. 267, No. 13, July 2000	
		SAID, et al., "The anti-HIV cytokine midkine binds the cell surface-expressed nucleolin as a low affinity receptor", <i>Journal of Biological Chemistry</i> , Vol. 277, No. 40, pages 37492-37498, October 4, 2002	
		STOICA, et al., "Midkine binds to anaplastic lymphoma kinase (ALK) and acts as a growth factor for different cell types", <i>Journal of Biological Chemistry</i> , Vol. 277, No. 39, pages 35990-35998, September 27, 2002	
		IKEDA, et al., "Effects of midkine during in vitro maturation of bovine oocytes on subsequent developmental competence", <i>Biology of Reproduction</i> , Vol. 63, No. 4, pages 1067-1074, October 2000	



Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	
				Filing Date	
				First Named Inventor	
				Art Unit	
				Examiner Name	
Sheet	2	of	2	Attorney Docket Number	031896-004000 (AM100990)

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	U.S. Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		KATO, et al., "Increased midkine expression in intrahepatic cholangiocarcinoma: Immunohistochemical and in situ hybridization analyses", <i>Liver</i> , Vol. 20, No. 3, June 2000	
		TSUTSUI, et al., "A New Family of Heparin-Binding Factors Strong Conservation of Midkine MK Sequences Between the Human and the Mouse", <i>Biochemical and Biophysical Research Communications</i> , Vol. 176, No. 2, pages 792-797,	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at 222.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.